ConductScience.org, home

Comparison · NCT02307916-caed0ef4

FGF-2 vs Placebo: Number of Patients With Tympanic Membrane Closure Following Treatment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. FGF-2 vs Placebo: Number of Patients With Tympanic Membrane Closure Following Treatment. Trial comparisons, record NCT02307916-caed0ef4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02307916-caed0ef4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5750.4220.715wilson
Risk in group 20.7140.4540.883wilson
Risk difference, group 1 minus group 2-0.139-0.3670.157newcombe hybrid score
Risk ratio, group 1 over group 20.8050.5261.23log
Odds ratio, group 1 over group 20.5410.1452.02log
Number needed to treat, for one fewer participant with the outcome on FGF-2 than on Placebo7.18from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1FGF-2
FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.~FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
2340OG000
Group 2PlaceboEqual concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.~Placebo: Placebo comparator using a sterile saline solution.1014OG001

Outcome

Type
PRIMARY
Title
Number of Patients With Tympanic Membrane Closure Following Treatment
Description
The efficacy of the treatment is determined by the number of patients whose tympanic membrane perforations closed after study treatments. Subjects from both treatment arms received up to three treatments before determining non-closure of the tympanic membrane.
Time frame
~60 days
Population

Source ClinicalTrials.gov

Trial

Title
Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations
NCT number
NCT02307916
Phases
PHASE2
Conditions
Tympanic Membrane Perforation
Interventions
FGF-2, Placebo
Lead sponsor
D. Bradley Welling, MD, PhD
Results first posted
2020-06-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02307916-caed0ef4